Literature DB >> 26344583

Secondary Enucleations for Uveal Melanoma: A 7-Year Retrospective Analysis.

Ido Didi Fabian1, Oren Tomkins-Netzer2, Ian Stoker3, Amit K Arora4, Mandeep S Sagoo5, Victoria M L Cohen4.   

Abstract

PURPOSE: To describe the indications for secondary enucleations in uveal melanoma and analyze associations and outcomes.
DESIGN: Retrospective interventional case series.
METHODS: Data of patients who underwent secondary enucleation for uveal melanoma in the London Ocular Oncology Service, between 2008 and 2014, were retrieved from medical records analyzed. Cox regression model was performed to analyze associations with secondary enucleation and metastases and Kaplan-Meier estimates to assess the probability of metastatic spread and death.
RESULTS: During the study period 515 enucleations were performed for uveal melanoma, 99 (19%) of which were secondary enucleations. Tumors were located at the ciliary body in 21 eyes (21%), juxtapapillary in 31 (31%), and choroid elsewhere in 47 (48%). Primary treatment included Ru(106) plaque radiotherapy, proton beam radiotherapy, and transpupillary thermotherapy in 85, 11, and 3 eyes, respectively. Indications for secondary enucleation were tumor recurrence in 60 (61%), neovascular glaucoma in 21 (21%), and tumor nonresponse in 18 eyes (18%). Twenty patients (20%) were diagnosed with metastasis and 12 out of 20 died of metastatic spread. On multivariate analysis, juxtapapillary tumor location was found to associate with tumor nonresponse (P = .004) and nonresponding patients with metastatic spread (P = .04).
CONCLUSIONS: Indications for secondary enucleations for uveal melanoma were tumor recurrence, neovascular glaucoma, and tumor nonresponse. This review identified a possible high-risk group (nonresponse), which proved radioresistant to treatment. These tumors were more frequently found in the juxtapapillary location and were associated with metastatic spread.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26344583     DOI: 10.1016/j.ajo.2015.08.034

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

1.  Neovascular glaucoma after proton beam therapy of choroidal melanoma: incidence and risk factors.

Authors:  Aline I Riechardt; Daniel Pilger; Dino Cordini; Ira Seibel; Enken Gundlach; Annette Hager; Antonia M Joussen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-07-18       Impact factor: 3.117

2.  Optic Disc Dose Comparison Between 125I and 103Pd Collaborative Ocular Melanoma Study (COMS) Plaques Based on Current Clinical Practice.

Authors:  Yongsook C Lee; Shih-Chi Lin; Yongbok Kim
Journal:  Cureus       Date:  2021-06-28

3.  A practical approach to estimating optic disc dose and macula dose without treatment planning in ocular brachytherapy using 125I COMS plaques.

Authors:  Yongsook C Lee; Shih-Chi Lin; Yongbok Kim
Journal:  Radiat Oncol       Date:  2018-11-13       Impact factor: 3.481

4.  Retrospective analysis of secondary enucleation for uveal melanoma after plaque radiotherapy.

Authors:  Heng Wang; Ruiheng Zhang; Yining Wang; Rongtian Chen; Yueming Liu; Yang Li; Wenbin Wei
Journal:  BMC Ophthalmol       Date:  2022-04-09       Impact factor: 2.209

Review 5.  Choroidal melanoma: A short review with an Indian perspective.

Authors:  Bikramjit P Pal; Saili Garge; Vikas Khetan
Journal:  Oman J Ophthalmol       Date:  2017 Sep-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.